Abstract
Peptides are the smallest antigenic components that are recognized by T cells when presented in MHC molecules on the cell surface. After the identification of peptides from tumor associated and tumor specific antigens, the exploration of the use of peptides in immunotherapy of cancer was instigated. From initial exploration of peptide-mediated induction of immune responses in mice, the peptide based vaccines have evolved to clinical testing in cancer patients. Many different clinical trials have been performed to address the ability of peptide-based vaccines to induce both clinical and immunological responses in patients. This review will provide an overview of the results of the majority of the clinical trials with peptide-based vaccines directed against various antigens in patients with solid tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Frontiers in bioscience : a journal and virtual library
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
